Combining conventional therapy with immunotherapy: A risky business?
- 1 May 2019
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 113, 41-44
Abstract
No abstract availableKeywords
Funding Information
- Olivia Fund (2017/LUF/00135)
- Amgen Chair for Therapeutic Advances in Ovarian Cancer (2017/LUF/00069)
This publication has 17 references indexed in Scilit:
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- Immune Priming of the Tumor Microenvironment by RadiationTrends in Cancer, 2016
- The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancerJournal for ImmunoTherapy of Cancer, 2015
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer AgentsCancer Cell, 2015
- Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian CancerCancer Research, 2015
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnnals of Oncology, 2012
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Ovarian cancer cytoreduction induces changes in T cell population subsets reducing immunosuppressionJournal of Cellular and Molecular Medicine, 2010
- Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survivalGynecologic Oncology, 2008